

Philip N Newsome

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/519342/publications.pdf>

Version: 2024-02-01

219
papers

21,481
citations

19657

61
h-index

10445

139
g-index

260
all docs

260
docs citations

260
times ranked

20658
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	12.1	195
2	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2022, 75, 219-228.	7.3	107
3	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
4	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	13.7	257
5	Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. <i>Lancet Respiratory Medicine</i> , the, 2022, 10, 255-266.	10.7	32
6	Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEQ single-arm Phase II trial. <i>Efficacy and Mechanism Evaluation</i> , 2022, 9, 1-54.	0.7	2
7	Why are there no strategies for NAFLD?. <i>Journal of Hepatology</i> , 2022, 76, 763-764.	3.7	3
8	A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124.	27.0	833
9	Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 185-198.	8.1	130
10	Optimising referral pathways for patients with non-alcoholic fatty liver disease in the UK. <i>British Journal of Health Care Management</i> , 2021, 27, 62-70.	0.2	1
11	Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018. <i>European Journal of Health Economics</i> , 2021, 22, 505-518.	2.8	16
12	Disease burden and economic impact of diagnosed nonâ€“alcoholic steatohepatitis in five European countries in 2018: A costâ€“ofâ€“illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242.	3.9	76
13	New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK. <i>Lancet</i> , The, 2021, 397, 1770-1780.	13.7	18
14	Administrative Coding in Electronic Health Care Recordâ€“Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	7.3	102
15	A scoping review of patient and public perspectives on cell and gene therapies. <i>Regenerative Medicine</i> , 2021, 16, 1005-1017.	1.7	0
16	Safety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in patients with cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , .	4.4	3
17	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785.	3.7	149
18	Fat and Fibrosis: Does Empagliflozin Impair the Progression of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus?. <i>Digestive Diseases and Sciences</i> , 2020, 65, 342-344.	2.3	4

#	ARTICLE	IF	CITATIONS
19	2020 “ A new decade of innovation for EASL. <i>Journal of Hepatology</i> , 2020, 72, 8.	3.7	0
20	Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK. <i>Lancet</i> , The, 2020, 395, 226-239.	13.7	53
21	Commentary: advances in the pharmacotherapy of NASH” anti”diabetic drugs and beyond. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 199-200.	3.7	0
22	Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020, 97, 106174.	1.8	25
23	Alcoholic hepatitis and metabolic disturbance in female mice : a more tractable model than <i>Nrf2-/-</i> animals. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	2.4	4
24	Administration of Human MSC-Derived Extracellular Vesicles for the Treatment of Primary Sclerosing Cholangitis: Preclinical Data in MDR2 Knockout Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8874.	4.1	15
25	The times they are a-changin' (for NAFLD as well). <i>Journal of Hepatology</i> , 2020, 73, 1307-1309.	3.7	45
26	Severe neurological crisis in adult patients with Tyrosinemia type 1. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1732-1737.	3.7	5
27	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. <i>JHEP Reports</i> , 2020, 2, 100169.	4.9	120
28	Effects of Epeleuton, a Novel Synthetic Second-Generation n-3 Fatty Acid, on Non-Alcoholic Fatty Liver Disease, Triglycerides, Glycemic Control, and Cardiometabolic and Inflammatory Markers. <i>Journal of the American Heart Association</i> , 2020, 9, e016334.	3.7	17
29	Cellular therapies for the treatment of immune-mediated GI and liver disease. <i>British Medical Bulletin</i> , 2020, 136, 127-141.	6.9	4
30	Patient and public perspectives on cell and gene therapies: a systematic review. <i>Nature Communications</i> , 2020, 11, 6265.	12.8	38
31	Editorial: rethinking cardiovascular risk factors in NAFLD with advanced fibrosis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 987-988.	3.7	1
32	The economic cost and health burden of non-alcoholic steatohepatitis in the EU5 countries. <i>Digestive and Liver Disease</i> , 2020, 52, e33-e34.	0.9	2
33	The Delivery of Multipotent Adult Progenitor Cells to Extended Criteria Human Donor Livers Using Normothermic Machine Perfusion. <i>Frontiers in Immunology</i> , 2020, 11, 1226.	4.8	40
34	Mesenchymal Stromal Cells, a New Player in Reducing Complications From Liver Transplantation?. <i>Frontiers in Immunology</i> , 2020, 11, 1306.	4.8	7
35	Sarcopenia in nonalcoholic fatty liver disease: new challenges for clinical practice. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 197-205.	3.0	27
36	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1.	1.3	1,840

#	ARTICLE	IF	CITATIONS
37	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	8.1	411
38	Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 158, 1611-1625.e12.	1.3	575
39	Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. <i>Journal of Hepatology</i> , 2020, 73, 231-240.	3.7	49
40	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	3.7	2,171
41	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. <i>JHEP Reports</i> , 2020, 2, 100113.	4.9	378
42	Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors. <i>PLoS ONE</i> , 2020, 15, e0241357.	2.5	4
43	Inhibition of vascular adhesion protein-1 modifies hepatic steatosis in vitro and in vivo. <i>World Journal of Hepatology</i> , 2020, 12, 931-948.	2.0	7
44	1472-P: Clinical Profile of Nonalcoholic Fatty Liver Disease in Adults with Type 2 Diabetes Mellitus. <i>Diabetes</i> , 2020, 69, .	0.6	0
45	Cell Therapy for Liver Disease: From Promise to Reality. <i>Seminars in Liver Disease</i> , 2020, 40, 411-426.	3.6	2
46	Title is missing!. , 2020, 15, e0241357.		0
47	Title is missing!. , 2020, 15, e0241357.		0
48	Title is missing!. , 2020, 15, e0241357.		0
49	Title is missing!. , 2020, 15, e0241357.		0
50	Obesity in acute alcoholic hepatitis increases morbidity and mortality. <i>EBioMedicine</i> , 2019, 45, 511-518.	6.1	28
51	Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 193-203.	3.7	112
52	Investigation of jaundice. <i>Medicine</i> , 2019, 47, 713-717.	0.4	5
53	THU-013-Investigating the potential immunomodulatory role of mesenchymal stromal cells in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e166.	3.7	0
54	THU-079-Study of anti-fibrotic activity of human umbilical-cord tissue-derived mesenchymal stromal cells during fibrogenesis or resolution in murine models of liver fibrosis. <i>Journal of Hepatology</i> , 2019, 70, e194.	3.7	0

#	ARTICLE	IF	CITATIONS
55	Resolving the fibrotic niche of human liver cirrhosis at single-cell level. <i>Nature</i> , 2019, 575, 512-518.	27.8	946
56	A Comparison of Phenotypic and Functional Properties of Mesenchymal Stromal Cells and Multipotent Adult Progenitor Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1952.	4.8	37
57	EASL Clinical Practice Guideline: Occupational liver diseases. <i>Journal of Hepatology</i> , 2019, 71, 1022-1037.	3.7	22
58	The role of stem cells in liver injury and repair. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 623-631.	3.0	15
59	Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study. <i>Journal of Hepatology</i> , 2019, 71, 313-322.	3.7	212
60	Editorial: early and late mortality following unscheduled admissions for severe liver disease across England and Wales. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1365-1366.	3.7	0
61	GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>Journal of Hepatology</i> , 2019, 70, e5.	3.7	39
62	LBP-24-Safety, tolerability and efficacy of volixibat, an apical sodium-dependent bile acid transporter inhibitor, in adults with nonalcoholic steatohepatitis: 24-week interim analysis results from a phase 2 study. <i>Journal of Hepatology</i> , 2019, 70, e152-e153.	3.7	2
63	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 156, 1717-1730.	1.3	777
64	938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH. <i>American Journal of Gastroenterology</i> , 2019, 114, S546-S546.	0.4	1
65	High incidence of hepatocellular carcinoma and postoperative complications in patients with nonalcoholic steatohepatitis as a primary indication for deceased liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 205-210.	1.6	11
66	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	13.7	818
67	Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 70, 711-724.	7.3	305
68	Haematopoietic stem cells in cirrhosis – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 298-299.	8.1	0
69	Systematic review: the natural history of alpha ₁ -antitrypsin deficiency, and associated liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 877-885.	3.7	67
70	Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells. <i>Stem Cells</i> , 2018, 36, 602-615.	3.2	384
71	Mesenchymal stromal cell therapy for liver diseases. <i>Journal of Hepatology</i> , 2018, 68, 1272-1285.	3.7	144
72	Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 631-644.	3.7	77

#	ARTICLE	IF	CITATIONS
73	Novel insights into mechanisms of disease progression. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 71-72.	17.8	23
74	Algorithm to identify patients with an activity grade > 2 in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD)-development in a large prospective multicenter UK study. Journal of Hepatology, 2018, 68, S552-S553.	3.7	1
75	Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet, The, 2018, 391, 1097-1107.	13.7	140
76	Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 25-36.	8.1	113
77	Guidelines on the management of abnormal liver blood tests. Gut, 2018, 67, 6-19.	12.1	320
78	Monocytic Cells Phagocytose Therapeutic Mesenchymal Stem Cells, which Induces Polarization, Relocation and Immune Regulation. Transplantation, 2018, 102, S206.	1.0	0
79	The human lymph node microenvironment unilaterally regulates T-cell activation and differentiation. PLoS Biology, 2018, 16, e2005046.	5.6	78
80	Presentation and prognosis of liver disease in alpha-1 antitrypsin deficiency. Expert Review of Gastroenterology and Hepatology, 2018, 12, 745-747.	3.0	10
81	Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in Europe. Journal of Hepatology, 2018, 68, S24-S25.	3.7	3
82	Performance of controlled attenuation parameter (CAP) to assess steatosis in a large prospective multicentre UK study of patients with non-alcoholic fatty liver disease (NAFLD). Journal of Hepatology, 2018, 68, S98.	3.7	0
83	The effect of semaglutide on liver enzymes in subjects with obesity and elevated alanine aminotransferase: Data from a randomised Phase 2 trial. Journal of Hepatology, 2018, 68, S581.	3.7	2
84	Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansion. Cytotherapy, 2018, 20, 919-929.	0.7	19
85	CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. American Journal of Physiology - Renal Physiology, 2018, 314, G483-G493.	3.4	46
86	Sub-cutaneously delivered mesenchymal stromal cells and down-regulation of activated vascular endothelium – a novel, clinically ready, therapeutic approach to treating cholestatic liver disease. Journal of Hepatology, 2018, 68, S5.	3.7	0
87	3D human liver tissue from pluripotent stem cells displays stable phenotype in vitro and supports compromised liver function in vivo. Archives of Toxicology, 2018, 92, 3117-3129.	4.2	89
88	Non-alcoholic fatty liver disease and the interface between primary and secondary care. The Lancet Gastroenterology and Hepatology, 2018, 3, 509-517.	8.1	106
89	Fumarylacetoacetate Hydrolase Knock-out Rabbit Model for Hereditary Tyrosinemia Type 1. Journal of Biological Chemistry, 2017, 292, 4755-4763.	3.4	15
90	The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016. Digestive Diseases, 2017, 35, 371-376.	1.9	6

#	ARTICLE	IF	CITATIONS
91	Aging of bone marrowâ€” and umbilical cordâ€”derived mesenchymal stromal cells during expansion. <i>Cytotherapy</i> , 2017, 19, 798-807.	0.7	65
92	Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. <i>Frontline Gastroenterology</i> , 2017, 8, 252-259.	1.8	22
93	Combining renewable human liver tissue and novel extracorporeal devices to deliver mammalian liver support. <i>Journal of Hepatology</i> , 2017, 66, S334-S335.	3.7	0
94	Sphingosine-1-Phosphate Prevents Egress of Hematopoietic Stem Cells From Liver to Reduce Fibrosis. <i>Gastroenterology</i> , 2017, 153, 233-248.e16.	1.3	48
95	Caution in Using Non-Invasive Scoring Systems in NAFLD Beyond Highly Selected Study Populations. <i>American Journal of Gastroenterology</i> , 2017, 112, 653-654.	0.4	3
96	New metrics for the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , 2017, 389, 2053-2080.	13.7	33
97	Development of a novel murine model of acute alcoholic hepatitis. <i>Journal of Hepatology</i> , 2017, 66, S115.	3.7	0
98	Ethnicity and outcomes in non alcoholic fatty liver disease: prospective evaluation of 1500 cases. <i>Journal of Hepatology</i> , 2017, 66, S589.	3.7	0
99	Editorial: liver transplantation in patients with nonâ€”alcoholic fatty liver disease and obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 459-460.	3.7	1
100	Review article: new treatments in nonâ€”alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 494-507.	3.7	50
101	Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. <i>Stem Cell Research and Therapy</i> , 2017, 8, 140.	5.5	84
102	A Modified Protocol for the Isolation of Primary Human Hepatocytes with Improved Viability and Function from Normal and Diseased Human Liver. <i>Methods in Molecular Biology</i> , 2017, 1506, 61-73.	0.9	3
103	Editorial: optimising nonâ€”invasive screening for advanced liver fibrosis in NAFLD. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 899-900.	3.7	0
104	Changes in human hepatic metabolism in steatosis and cirrhosis. <i>World Journal of Gastroenterology</i> , 2017, 23, 2685.	3.3	35
105	PWE-038â€”Validation of Multiparametric MRI in The Assessment and Staging of Non-Alcoholic Fatty Liver Disease: Abstract PWE-038 Table 1. <i>Gut</i> , 2016, 65, A157.2-A158.	12.1	0
106	Identifying patients with nonalcoholic steatohepatitis that are nonresponders to therapy. <i>Hepatology</i> , 2016, 64, 2265-2266.	7.3	4
107	Dissecting cellulitis of the scalp treated with tumour necrosis factor-Î± inhibitors: experience with two agents. <i>British Journal of Dermatology</i> , 2016, 174, 916-918.	1.5	24
108	Serum alkaline phosphatase in multidrug resistance 2 (Mdr2â€”/â€”) knockout mice is strain specific. <i>Hepatology</i> , 2016, 63, 346-346.	7.3	2

#	ARTICLE	IF	CITATIONS
109	Mesenchymal stromal cells and liver fibrosis: a complicated relationship. <i>FASEB Journal</i> , 2016, 30, 3905-3928.	0.5	67
110	Clinical effectiveness of cell therapies in patients with chronic liver disease and acute-on-chronic liver failure: a systematic review protocol. <i>Systematic Reviews</i> , 2016, 5, 100.	5.3	17
111	Non-alcoholic fatty liver disease in 2016. <i>British Medical Bulletin</i> , 2016, 119, 143-156.	6.9	61
112	Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 110, hcw151.	0.5	26
113	AAV-mediated liver-directed gene therapy for Acute Intermittent Porphyria: It is safe but is it effective?. <i>Journal of Hepatology</i> , 2016, 65, 666-667.	3.7	6
114	Liraglutide for patients with non-alcoholic steatohepatitis – Authors' reply. <i>Lancet, The</i> , 2016, 387, 2379.	13.7	1
115	Steatosis and liver stiffness measurements using transient elastography. <i>Hepatology</i> , 2016, 64, 700-700.	7.3	9
116	Liver regeneration – mechanisms and models to clinical application. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 473-485.	17.8	278
117	Murine Models of Acute Alcoholic Hepatitis and Their Relevance to Human Disease. <i>American Journal of Pathology</i> , 2016, 186, 748-760.	3.8	29
118	Entering the GOLDEN Age for Therapies in NASH. <i>Gastroenterology</i> , 2016, 150, 1073-1076.	1.3	4
119	Non-alcoholic fatty liver disease and liver transplantation. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 1208-1223.	3.4	40
120	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. <i>Lancet, The</i> , 2016, 387, 679-690.	13.7	1,397
121	Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2016, 64, 399-408.	3.7	308
122	CD248/endosialin critically regulates hepatic stellate cell proliferation during chronic liver injury via a PDGF-regulated mechanism. <i>Gut</i> , 2016, 65, 1175-1185.	12.1	67
123	Development of a Multi-Modal Optical Imaging System. , 2016, , .		0
124	O069 : Evidence for a role of CCR2 in human non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2015, 62, S225.	3.7	0
125	Mesenchymal stromal cell therapy in liver disease: opportunities and lessons to be learnt?. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, G791-G800.	3.4	32
126	Pretreatment of Mesenchymal Stem Cells Manipulates Their Vasculoprotective Potential While Not Altering Their Homing Within the Injured Gut. <i>Stem Cells</i> , 2015, 33, 2785-2797.	3.2	33

#	ARTICLE	IF	CITATIONS
127	Mesenchymal stromal cells – Where art thou?. <i>Journal of Hepatology</i> , 2015, 63, 1306-1308.	3.7	1
128	Implementation of the Lancet Standing Commission on Liver Disease in the UK. <i>Lancet, The</i> , 2015, 386, 2098-2111.	13.7	76
129	A concise review of non-alcoholic fatty liver disease. <i>Atherosclerosis</i> , 2015, 239, 192-202.	0.8	234
130	Trials of obeticholic acid for non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2015, 386, 28.	13.7	4
131	Non-alcoholic fatty liver disease: when to intervene and with what. <i>Clinical Medicine</i> , 2015, 15, 186-190.	1.9	17
132	REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2015, 5, e007700-e007700.	1.9	28
133	Editorial: treatment for <scp>NASH</scp> – helping the liver or helping the heart?. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 487-487.	3.7	3
134	Investigation of jaundice. <i>Medicine</i> , 2015, 43, 573-576.	0.4	10
135	Hepatocyte cell therapy in liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1261-1272.	3.0	19
136	Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. <i>Lancet, The</i> , 2014, 384, 1953-1997.	13.7	492
137	<scp>SOS</scp> Liver damage; calling all haematopoietic stem cells. <i>Liver International</i> , 2014, 34, 1-3.	3.9	10
138	Bone Marrow Stem Cell Therapy for Liver Disease. <i>Digestive Diseases</i> , 2014, 32, 494-501.	1.9	6
139	Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 33-41.	0.5	41
140	Non-enzymatic dissociation of human mesenchymal stromal cells improves chemokine-dependent migration and maintains immunosuppressive function. <i>Cytotherapy</i> , 2014, 16, 545-559.	0.7	30
141	Generation of knockout rabbits using transcription activator-like effector nucleases. <i>Cell Regeneration</i> , 2014, 3, 3:3.	2.6	34
142	Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. <i>Journal of Inherited Metabolic Disease</i> , 2014, 37, 745-752.	3.6	55
143	Development of Hepatocellular Carcinoma in a Murine Model of Nonalcoholic Steatohepatitis Induced by Use of a High-Fat/Fructose Diet and Sedentary Lifestyle. <i>American Journal of Pathology</i> , 2014, 184, 1550-1561.	3.8	91
144	Stem cells for liver regeneration. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2014, 107, 417-421.	0.5	19

#	ARTICLE	IF	CITATIONS
145	Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 651-660.	4.4	50
146	Dysregulated hepatic expression of glucose transporters in chronic disease: contribution of semicarbazide-sensitive amine oxidase to hepatic glucose uptake. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, G1180-G1190.	3.4	22
147	NAFLD Is Underrecognized in The Primary Care Setting: UK Experience. <i>American Journal of Gastroenterology</i> , 2014, 109, 1500-1501.	0.4	5
148	Bone marrow mesenchymal stem cells and liver regeneration: believe the hypoxia!. <i>Stem Cell Research and Therapy</i> , 2013, 4, 108.	5.5	7
149	Crosstalk Between Mesenchymal Stem Cells and Endothelial Cells Leads to Downregulation of Cytokine-Induced Leukocyte Recruitment. <i>Stem Cells</i> , 2013, 31, 2690-2702.	3.2	61
150	Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 234-242.	3.7	204
151	Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. <i>BMJ Open</i> , 2013, 3, e003995.	1.9	41
152	Loss of 5 α -Reductase Type 1 Accelerates the Development of Hepatic Steatosis but Protects Against Hepatocellular Carcinoma in Male Mice. <i>Endocrinology</i> , 2013, 154, 4536-4547.	2.8	67
153	Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study. <i>Health Technology Assessment</i> , 2013, 17, i-xiv, 1-307.	2.8	58
154	PMO-115...ANTI-B1-integrin antibodies improve survival of isolated human hepatocytes significantly increasing both adhesion to hepatic sinusoidal endothelium under flow and engraftment in murine liver following transplantation. <i>Gut</i> , 2012, 61, A119.2-A120.	12.1	0
155	410 P1-INTEGRINS AND BASAL CELL ADHESION MOLECULE PLAY A ROLE IN THE ADHESION OF ES CELL-DERIVED HEPATOCYCLE-LIKE CELLS TO ECM AND HEPATIC SINUSOIDAL CELLS. <i>Journal of Hepatology</i> , 2012, 56, S164.	3.7	0
156	Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. <i>Gut</i> , 2012, 61, 484-500.	12.1	71
157	Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. <i>Journal of Hepatology</i> , 2012, 56, 234-240.	3.7	273
158	New horizons for stem cell therapy in liver disease. <i>Journal of Hepatology</i> , 2012, 56, 496-499.	3.7	88
159	Oral diagnosis and treatment planning: part 1. Introduction. <i>British Dental Journal</i> , 2012, 213, 15-19.	0.6	13
160	PMO-134...Basal cell adhesion molecule and b1-integrins regulate the adhesion of ES cell-derived hepatocyte-like cells to extracellular matrix and hepatic sinusoidal cells. <i>Gut</i> , 2012, 61, A127.2-A127.	12.1	0
161	Human mesenchymal stem cells are recruited to injured liver in a β 1-integrin and CD44 dependent manner. <i>Hepatology</i> , 2012, 56, 1063-1073.	7.3	57
162	The diagnosis of non-alcoholic fatty liver disease: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 205-206.	3.7	0

#	ARTICLE	IF	CITATIONS
163	Long-Term Impact of Liver Transplantation on Respiratory Function and Nutritional Status in Children and Adults With Cystic Fibrosis. <i>American Journal of Transplantation</i> , 2012, 12, 954-964.	4.7	47
164	Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. <i>Liver Transplantation</i> , 2012, 18, 195-200.	2.4	95
165	A Switch in Hepatic Cortisol Metabolism across the Spectrum of Non Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2012, 7, e29531.	2.5	83
166	Stem Cell Technology and Cell Based Therapies. , 2012, , 115-137.		0
167	Isolation of Primary Human Hepatocytes from Normal and Diseased Liver Tissue: A One Hundred Liver Experience. <i>PLoS ONE</i> , 2011, 6, e18222.	2.5	114
168	P85 Human mesenchymal stem cells bind preferentially to injured liver in a $\alpha 1$ -integrin and CD44 dependent manner. <i>Gut</i> , 2011, 60, A39-A39.	12.1	0
169	P79 Plasma succinylacetone is raised after liver transplantation for tyrosinaemia type 1 and is associated with reduced porphobilinogen synthase activity suggesting it is functional. <i>Gut</i> , 2011, 60, A36-A37.	12.1	0
170	P86 5 α -reductase-1 knockout promotes steatosis but protects against hepatocarcinogenesis in a murine model of NAFLD. <i>Gut</i> , 2011, 60, A39-A40.	12.1	0
171	Liver Transplantation From Donors With Acute Intermittent Porphyria. <i>Annals of Internal Medicine</i> , 2011, 154, 571.	3.9	60
172	Current therapeutic strategies in non-alcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2011, 13, 692-702.	4.4	92
173	Systematic review: the diagnosis and staging of non α lcoholic fatty liver disease and non α lcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 525-540.	3.7	254
174	Persistence of functional hepatocyte-like cells in immune-compromised mice. <i>Liver International</i> , 2011, 31, 254-262.	3.9	37
175	Use of hepatocyte and stem cells for treatment of post-resectional liver failure: are we there yet?. <i>Liver International</i> , 2011, 31, 773-784.	3.9	22
176	Investigation of jaundice. <i>Medicine</i> , 2011, 39, 518-522.	0.4	6
177	Unbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism. <i>Stem Cell Research</i> , 2011, 6, 92-102.	0.7	95
178	UK experience of liver transplantation for erythropoietic protoporphyria. <i>Journal of Inherited Metabolic Disease</i> , 2011, 34, 539-545.	3.6	27
179	Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: Time to reconsider immunosuppression regimens?. <i>Liver Transplantation</i> , 2011, 17, 1292-1298.	2.4	66
180	Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: Short-term and long-term outcomes. <i>Hepatology</i> , 2011, 54, 1891-1892.	7.3	12

#	ARTICLE	IF	CITATIONS
181	57 Mesenchymal stem cells inhibit recruitment of flowing neutrophils and lymphocytes by endothelial cells: roles of interleukin-6 and transforming growth factor- β . <i>Heart</i> , 2011, 97, e7-e7.	2.9	1
182	Summary of: An audit of dental prescriptions between clinics and dental laboratories. <i>British Dental Journal</i> , 2011, 211, 126-127.	0.6	0
183	Impaired gluconeogenesis in a porcine model of paracetamol induced acute liver failure. <i>World Journal of Gastroenterology</i> , 2011, 17, 1457.	3.3	10
184	Recurrence of nonalcoholic fatty liver disease after liver transplantation: It is common, but does it affect outcome?. <i>Liver Transplantation</i> , 2010, 16, 420-422.	2.4	11
185	Development of an invasively monitored porcine model of acetaminophen-induced acute liver failure. <i>BMC Gastroenterology</i> , 2010, 10, 34.	2.0	31
186	Bone Marrow Stem Cells Contribute to Alcohol Liver Fibrosis in Humans. <i>Stem Cells and Development</i> , 2010, 19, 1417-1425.	2.1	40
187	Pathogenesis of non-alcoholic fatty liver disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 71-83.	0.5	581
188	Orlistat for overweight subjects with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2009, 50, 321-321.	7.3	0
189	Adhesion of human haematopoietic (CD34+) stem cells to human liver compartments is integrin and CD44 dependent and modulated by CXCR3 and CXCR4. <i>Journal of Hepatology</i> , 2009, 51, 734-749.	3.7	33
190	844 POLYMER LIBRARY SCREENING IDENTIFIES AN EXTRACELLULAR MATRIX THAT PROMOTES AND STABILISES HUMAN EMBRYONIC STEM CELL-DERIVED HEPATOCYTE FUNCTION. <i>Journal of Hepatology</i> , 2009, 50, S307-S308.	3.7	0
191	Critical Review of Clinical Trials of Bone Marrow Stem Cells in Liver Disease. <i>Gastroenterology</i> , 2008, 135, 438-450.	1.3	196
192	153 HIGHLY EFFICIENT DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS TO FUNCTIONAL HEPATOCYTES REQUIRES ACTIVIN A AND WNT3A SIGNALING. <i>Journal of Hepatology</i> , 2008, 48, S67.	3.7	0
193	Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 12301-12306.	7.1	392
194	Emerging drugs for complications of end-stage liver disease. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 159-174.	2.4	1
195	The Inhibitory Role of Stromal Cell Mesenchyme on Human Embryonic Stem Cell Hepatocyte Differentiation is Overcome by Wnt3a Treatment. <i>Cloning and Stem Cells</i> , 2008, 10, 331-340.	2.6	30
196	Yet Another Role for Mesenchymal Stem Cells?. <i>Transplantation</i> , 2008, 85, 1548-1549.	1.0	0
197	A Biochemical Prognostic Model of Outcome in Paracetamol-Induced Acute Liver Injury. <i>Transplantation</i> , 2005, 80, 1712-1717.	1.0	27
198	Hematopoietic stem cell trafficking in liver injury. <i>FASEB Journal</i> , 2005, 19, 1225-1231.	0.5	101

#	ARTICLE	IF	CITATIONS
199	Potential of Hematopoietic Stem Cell Therapy in Hepatology: A Critical Review. <i>Stem Cells</i> , 2004, 22, 897-907.	3.2	58
200	Serum from patients with fulminant hepatic failure causes hepatocyte detachment and apoptosis by a α 1-integrin pathway. <i>Hepatology</i> , 2004, 40, 636-645.	7.3	24
201	Hepatic Oval Cells: Helping Redefine a Paradigm in Stem Cell Biology. <i>Current Topics in Developmental Biology</i> , 2004, 61, 1-28.	2.2	64
202	Biochemical prognostic markers of outcome in non-paracetamol-induced fulminant hepatic failure. <i>Transplantation</i> , 2004, 77, 200-205.	1.0	31
203	Effects of acute liver injury on blood coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 754-759.	3.8	74
204	Prognostic markers of outcome in non-acetaminophen overdose fulminant hepatic failure. <i>Gastroenterology</i> , 2003, 124, A756.	1.3	0
205	Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion. <i>Gastroenterology</i> , 2003, 124, 1891-1900.	1.3	303
206	Value gaps in dental practice. <i>Journal of the American Dental Association</i> , 2003, 134, 1500-1504.	1.5	1
207	From I Don't Care to Customer Care. An Evolution in Patient Expectation. <i>Dental Update</i> , 2003, 30, 488-490.	0.2	3
208	A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases. <i>Biomedical Chromatography</i> , 2002, 16, 365-372.	1.7	40
209	Acute liver failure serum reduces hepatocyte-matrix adhesion by a cell death-independent mechanism. <i>Journal of Hepatology</i> , 2001, 34, 29.	3.7	1
210	Referral patterns and social deprivation in paracetamol-induced liver injury in Scotland. <i>Lancet</i> , The, 2001, 358, 1612-1613.	13.7	30
211	Prothrombin time to assess fulminant hepatic failure. <i>Lancet</i> , The, 2001, 358, 2172.	13.7	7
212	Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. <i>Liver Transplantation</i> , 2001, 7, 2-10.	2.4	88
213	An improved ex vivo method of primary porcine hepatocyte isolation for use in bioartificial liver systems. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 923-930.	1.6	14
214	Animal models of fulminant hepatic failure: A critical evaluation. <i>Liver Transplantation</i> , 2000, 6, 21-31.	2.4	112
215	Low serum retinol levels are associated with hepatocellular carcinoma in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1295-1301.	3.7	62
216	Animal models of fulminant hepatic failure: A critical evaluation. <i>Liver Transplantation</i> , 2000, 6, 21-31.	2.4	11

#	ARTICLE	IF	CITATIONS
217	The inhibition of growth due to fulminant hepatic failure serum is not due to increased apoptosis/necrosis. <i>Journal of Hepatology</i> , 2000, 32, 59.	3.7	1
218	Platelet basal cytosolic calcium: The influence of plasma factors in cirrhosis. <i>Journal of Hepatology</i> , 1996, 25, 312-315.	3.7	7
219	The Orthogonal Orientation Shift and Spatial Filtering. <i>Perception</i> , 1995, 24, 513-524.	1.2	10